Skip to main content

Rationale for Antiretroviral Therapy for Treatment of Multiple Sclerosis

See the following dropbox link, or files below, for a number of scientific papers indicating that EBV is the cause and driver of MS disease activity, and on potential antiviral therapies.

Files

CD4-T-cells-restricted-to-DRB11501-recognize-two-EpsteinBarr-W9aAt4PtxoopXl0V5ZexGQ.pdf2.56 MB

EBV-specific-T-cell-responses-are-telling-us-gfpoOn-lE7cqSUjbClUe0g.pdf411.51 KB

Discoveries-beyond-molecular-mimicry-TPBy9geo4tHQbUDWljwJnA.pdf2.48 MB

Dysregulated-Epstein-Barr-virus-infection-in-the-multiple-sclerosis-brain-AK4WdrGmEjLISgfJ5hQaig.pdf4.28 MB

ebv-dysregulation-is-associated-with-immune-imbalance-in-multiple-sclerosis-1h7e_pzp-HLO1MJCRpC0yg.pdf765.02 KB

EBV-infection-and-HLA-DR15-jointly-drive-multiple-WkuWlYX8pCfxgaD5JCuHaA.pdf9.08 MB

Long-term-MRI-and-clinical-stability-in-an-HIV-positive-patient-with-multiple-sclerosis-on-tenofovir-lRIcs33yZyFIl8zfAx2_6Q.pdf1.56 MB

Probing-the-association-between-Multiple-Sclerosis-and-Epstein-Barr-Virus-from-a-therapeutic-perspective-PktFTpApMKSEiEizjio-Lg.pdf256.95 KB

Tenofovir-as-a-treatment-option-for-multiple-sclerosis-jYvgy2Ec7Ba76b0cH3LCYA.pdf468.13 KB

Tenofovir-prodrugs-potently-inhibit-EpsteinBarr-7tDr-mFP5xucg-OTNZF6Lg.pdf1.11 MB

the-role-of-epstein-barr-virus-in-multiple.1-DxtQwY5o_Q4tIkApSow7Ig.pdf339.87 KB

Unstable-EBV-latency-drives-inammation-in-KD5FPV4swB8QTe1FNorC5w.pdf1.43 MB

vivien-li-repurposing-licensed-drugs-with-activity-OzVtAKC2Aoh0168Pj-7s6Q.pdf710.56 KB

Antiviral-therapy-with-tenofovir-in-MS-EaRaj799zduhIir7F2x5VQ.pdf404.79 KB

Could-antiretrovirals-be-treating-EBV-in-MS-fGEWEw_FUUysDQHeaMM-Uw.pdf374.33 KB

EBV-and-multiple-sclerosis-moving-from-nmrGtse7I88crKiHvcR6NA.pdf7.11 MB

EBV-as-a-leading-cause-of-multiple-sclerosis-sBbi-qHcwmJuHsPauPKLRA.pdf466.37 KB

EBV-as-the-gluten-of-MS-hypothesis-provides-a-rationale-for-trialing-antiviral-therapies-_dZ84wvYbDPtepHyEVLJSQ.pdf268.77 KB

EBV-Early-Lytic-Antigens-EBNA2-and-PDL-1-in-Progressive-Multiple-Sclerosis-Brain-4ZDKBSV5_XN0XMWfKncRkw.pdf2.53 MB

Epstein-Barr-virus-as-a-cause-of-multiple-sclerosis-opportunities-for-prevention-and-therapy-yP-M-7irbpnfQeEcmi-Nxw.pdf1.71 MB

Epstein-Barr-Virus-Specific-CD8-T-Cells-Selectively-Infiltrate-the-Brain-in-Multiple-Sclerosis-A-XnEiYI-2rxDzn_rK9_7Q.pdf4.77 MB

HHV-6-and-EBV-reactivation-in-relapsing-remitting-ms-vYJVhhl8oOUaGGSTBQ6H1Q.pdf2.4 MB

HIV-and-lower-risk-of-multiple-sclerosis-kVzOmFTOzI0IfwfFS6f1dg.pdf327 KB

Increased-CD8-T-Cell-Response-to-Epstein-Barr-Virus-WJtv8CZ_-opvSgWEMbIeNw.pdf1.61 MB

In-the-era-of-antiviral-trials-for-MS-the-answer-lies-in-the-details-AcJfYc2QqYGmAW_kZy9qvg.pdf662.91 KB

Intrathecal-CD8-T-cells-of-multiple-sclerosis-f0a6lwa90AKzhqRAorZueA.pdf732.22 KB

longitudinal-analysis-reveals-high-prevalence-of-epstein-barr-virus-associated-with-multiple-sclerosis-W3ebvCZoQau2bP4KmZNllQ.pdf1.07 MB

Risk-of-Multiple-Sclerosis-in-People-Living-with-HIV-e5U5okCwKygzvEOT7xL7pg.pdf251.9 KB

The-case-for-targeting-latent-and-lytic-ztnW1_XcwPsTK0OkIsHXIw.pdf16.5 MB

When-does-multiple-sclerosis-start-kcXbLhFfqWaZTZo4Q0QLrQ.pdf536.48 KB

Evaluation-of-IL-1-and-IL-6-Expression-following-hD5TawuRfxOavPkBayPjmA.pdf413.11 KB

Heightened-EBV-immunity-and-SEf_atFYod7ZDklvHVQP_w.pdf1.91 MB

Latent-Lytic-and-Linked-to-Multiple-SclerosisHow-EBV-3j1FOHTOMsS2erC21Ak0sQ.pdf835.95 KB

ivind-torkildsen-antiviral-therapy-with-tenofovir-in-NJfmiln5SnoPLyon9qT8lg.pdf401.16 KB

Radiologic-and-clinical-stability-in-an-HIV-negative-MS-patient-after-tenofovir-b7lKqd6lx11gBvb_1oXGgQ.pdf284.72 KB

Seroreactivity-against-lytic-latent-and-possible-cross-8sWJ4adeWb_yQSqQwzNrew.pdf967.12 KB

Targeting-EBV-is-a-viable-therapeutic-strategy-in-MS-ZI2byqhG5Dlf_CCV1CU1gg.pdf507.45 KB

targeting-epstein-barr-virus-in-multiple-sclerosis-when-and-how--sh3kVekb6aQDj32xJW-r2g.pdf914.88 KB